Valuation: Insulet Corporation

Market Cap 1.06TCr 947.34Cr 873.98Cr 790.89Cr 1.48TCr 1,00700Cr 1.5TCr 10TCr 4.16TCr 53TCr 3.97TCr 3.88TCr 1,66900Cr P/E 2026 *
24.9x
P/E 2027 * 20x
Enterprise Value 1.06TCr 951.78Cr 878.08Cr 794.6Cr 1.49TCr 1,01200Cr 1.51TCr 10TCr 4.18TCr 53TCr 3.99TCr 3.9TCr 1,67700Cr EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.75x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+2.40%
1 week+2.96%
Current month+16.89%
1 month+14.80%
3 months-10.62%
6 months-4.70%
Current year-46.35%
1 week 146.62
Extreme 146.62
152.66
1 month 128.01
Extreme 128.01
152.66
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Director/Board Member 61 27/07/2015
Director/Board Member 54 20/10/2020
Director/Board Member 55 18/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/09/26 Free

Director

141 0.0002%
30/09/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%+2.96%-51.77%+14.29% 1.06TCr
+1.88%+2.01%-15.96%+12.62% 18TCr
+2.55%+1.52%-15.65%+19.03% 12TCr
+2.46%+0.54%+5.87%+39.87% 12TCr
+2.13%+0.44%-43.04%+8.15% 9.14TCr
+1.91%-2.35%-0.79%+76.15% 6.31TCr
-0.46%+0.42%+8.19%+82.97% 5.58TCr
+1.63%-1.04%+9.27%-21.17% 5.4TCr
+2.32%+1.63%-8.23%+47.17% 4.54TCr
+0.71%+2.17%-0.90%-6.27% 3.44TCr
Average +1.51%+0.73%-11.30%+27.28% 7.74TCr
Weighted average by Cap. +1.53%+0.79%-10.39%+26.37%

Financials

2026 *2027 *
Net sales 328.68Cr 294.39Cr 271.6Cr 245.78Cr 459.59Cr 31TCr 467.02Cr 3.24TCr 1.29TCr 16TCr 1.23TCr 1.21TCr 52TCr 373.29Cr 334.36Cr 308.46Cr 279.14Cr 521.97Cr 36TCr 530.41Cr 3.68TCr 1.47TCr 19TCr 1.4TCr 1.37TCr 59TCr
Net income 43Cr 38Cr 35Cr 32Cr 59Cr 4.05TCr 60Cr 419.19Cr 167.23Cr 2.12TCr 159.57Cr 156.18Cr 6.71TCr 53Cr 48Cr 44Cr 40Cr 75Cr 5.08TCr 76Cr 526.3Cr 209.96Cr 2.66TCr 200.35Cr 196.08Cr 8.43TCr
Net Debt 4.96Cr 4.44Cr 4.1Cr 3.71Cr 6.94Cr 472.54Cr 7.05Cr 49Cr 20Cr 247.31Cr 19Cr 18Cr 783.28Cr -32Cr -29Cr -27Cr -24Cr -45Cr -3.07TCr -46Cr -317.81Cr -126.79Cr -1.61TCr -120.98Cr -118.41Cr -5.09TCr
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
29/26/29 $152.50 +2.40% 12,97,218
28/26/28 $148.93 -0.60% 10,35,225
27/26/27 $149.83 +0.38% 9,43,833
26/26/26 $149.26 +0.17% 15,25,635
23/26/23 $149.01 +0.60% 8,03,141
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
152.50USD
Average target price
167.17USD
Spread / Average Target
+9.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insulet Corporation
  1. Stock Market
  2. Stocks
  3. PODD Stock